| Dr David Franklin Oakes, MD | |
|
2301 House Ave Ste 301, Cheyenne, WY 82001-3178 | |
| (307) 637-1600 | |
| Not Available |
| Full Name | Dr David Franklin Oakes |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 41 Years |
| Location | 2301 House Ave Ste 301, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083642987 | NPI | - | NPPES |
| 003871900 | Medicaid | ID | |
| 4883908 | Medicaid | NM | |
| 1083642987 | Other | TX | FIRSTCARE |
| 384320301 | Medicaid | TX | |
| 8JG587 | Other | TX | BCBS |
| 654414 | Other | TX | MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheyenne Regional Medical Center | Cheyenne, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cheyenne Regional Physicians Group Llc | 2961403639 | 92 |
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia", according to a study in the May 9 issue of Journal of the American Medical Association.
Massachusetts General Hospital, together with a coalition of 20 international sites in five countries, will create the world's largest registry of patients who have had optical coherence tomography of the coronary arteries.
› Verified 9 days ago
| Entity Name | Cheyenne Regional Physicians Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659458008 PECOS PAC ID: 2961403639 Enrollment ID: O20070123000486 |
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia", according to a study in the May 9 issue of Journal of the American Medical Association.
Massachusetts General Hospital, together with a coalition of 20 international sites in five countries, will create the world's largest registry of patients who have had optical coherence tomography of the coronary arteries.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Franklin Oakes, MD 1626 E Common St, New Braunfels, TX 78130-3156 Ph: (830) 620-1272 | Dr David Franklin Oakes, MD 2301 House Ave Ste 301, Cheyenne, WY 82001-3178 Ph: (307) 637-1600 |
News Archive
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia", according to a study in the May 9 issue of Journal of the American Medical Association.
Massachusetts General Hospital, together with a coalition of 20 international sites in five countries, will create the world's largest registry of patients who have had optical coherence tomography of the coronary arteries.
› Verified 9 days ago
Robert J. Sachs, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5050 Powderhouse Rd, Cheyenne, WY 82009 Phone: 307-634-1311 Fax: 307-634-1271 | |
Dr. Jamie Skrove, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7212 Commons Cir, Cheyenne, WY 82009 Phone: 307-635-4141 Fax: 307-635-6587 | |
Dale C Brentlinger, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2508 E Fox Farm Road, #1a, Cheyenne, WY 82007 Phone: 307-635-3618 Fax: 307-635-1442 | |
Sandra Abreu Guidry, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-638-0300 Fax: 307-638-0394 | |
Sebastine I Elendu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 House Ave, Suite 201, Cheyenne, WY 82001 Phone: 307-638-7757 | |
Hoo Feng Choo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 House Ave, Suite 201, Cheyenne, WY 82001 Phone: 307-638-7757 Fax: 307-637-8300 |